Compare Merck & Co., Inc. (MRK) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nucor Corporation — how do they compare? Merck & Co., Inc. trades at $130.55 (market cap $321.77B), while Nucor Corporation trades at $269.56 (market cap $61.93B). The key difference: Merck & Co., Inc. is far larger — about 5.2× Nucor Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | NUE | |
|---|---|---|
Market Cap | $321.77B | $61.93B |
Sector | Health | Basic Materials |
52-Week High | $131.84 | $274.74 |
52-Week Low | $77.60 | $131.78 |
Enterprise Value | $368.53B | $66.34B |
Dividend Yield | 2.61% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Nucor (NUE) trades at $274.61, up 0.73% today, with a bullish technical outlook and strong earnings beats in Q1 and Q2 2026. The stock shows robust fundamentals with a P/E of 21.7 and net income margin of 7.99%, supported by record steel shipments and higher prices. Recent news highlights its position near buy points and resilience in industrial demand.
Outlook is positive with analyst consensus favoring buy ratings (59.37%) and a $279.63 price target. Risks include cyclical steel demand and tariff impacts, but earnings growth and institutional support provide upside potential for investors seeking exposure to industrial recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
